Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

Phase 1

Completed

• Conditions: Diabetes; Diabetes Mellitus, Type 2
• Interventions: Drug: liraglutide; Drug: placebo

• Registration Number: NCT01509742
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

This trial is conducted in Europe. The aim of this trial is to examine the effect of NNC 90-1170 on the hypoglycaemic counterregulation in subjects with type 2 diabetes.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-04
• Primary Completion: 2001-11
• Study Completion: 2001-11
• Study First Submitted: 2012-01-06
• Study First Submitted QC: 2012-01-12
• Study First Posted: 2012-01-13
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-31
• Last Update Posted: 2024-02-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
NNC 90-1170	liraglutide	-
Placebo	placebo	-

Primary Outcome Measures

Name	Time	Method
Area under the Curve (AUC) glucagon

Secondary Outcome Measures

Name	Time	Method
Glucose
Adrenaline
Insulin secretion
Noradrenaline
Cortisol
Growth hormone
Adverse events

Trial Locations

Locations (1)

Novo Nordisk Investigational Site; 🇩🇪 Bad Lauterberg, Germany